Emergent BioSolutionsの空売り状況は、投資家がEmergent BioSolutionsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Emergent BioSolutions (NYSE:EBS) 株価情報, 空売り情報

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

Biotech

News

General

AEMD

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

During the last three months, 4 analysts shared their evaluations of Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Emergent BioSolutions, presenting an average target of $14.25, a high estimate of $15.00, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 12.47% from the previous average price target of $12.67.
<img src="https://www.benzinga.com/files/images/story/2025/1737464440_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Emergent BioSolutions by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Emergent BioSolutions. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Emergent BioSolutions compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Emergent BioSolutions's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Emergent BioSolutions's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EBS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Emergent BioSolutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Emergent BioSolutions</h2>
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
<h3>Understanding the Numbers: Emergent BioSolutions's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Emergent BioSolutions's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 7.5%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Emergent BioSolutions's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 40.45%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Emergent BioSolutions's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 25.66%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Emergent BioSolutions's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 7.68%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.3, Emergent BioSolutions faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target

Emergent BioSolutions Says It Gained Exclusive Commercial Rights To KLOXXADO (naloxone HCI) Nasal Spray From Hikma Pharmaceuticals

<ul>
<li>This option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga&#x2122;, with a maximum value of $704 million
<ul>
<li>Program progress and performance triggers $16.7 million contract option</li>
</ul>
</li>
</ul>

Contracts

Emergent BioSolutions Receives $16.7M Contract Option To Continue Development Collaboration With BARDA On Ebanga Treatment For Ebola

Emergent BioSolutions announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax&#xAE; (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025.

Emergent BioSolutions To Deliver BioThrax Vaccine Under $20M DoD Contract Option

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 0.7% on Monday.
The Dow traded down 0.67% to 42,702.02 while the NASDAQ fell 0.73% to 19,578.50. The S&amp;P 500 also fell, dropping, 0.72% to 5,928.08.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares rose by 0.2% on Monday.
In trading on Monday, consumer discretionary shares dipped by 1.2%.
Top Headline
U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 5% to $6.69. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 12% to $9.27. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 7% to $14.48. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vertical Aerospace Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) shares dropped 15% to $13.20. The company recently announced it has finalized an investment agreement for up to $50 million in new funding.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 41% to $7.92. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 31% to $0.42. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.34 while gold traded down 0.6% at $2,616.00.
Silver traded down 2% to $29.385 on Monday, while copper fell 0.8% to $4.0880.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.46%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.57%. Spain's IBEX 35 Index rose 0.05%, while London's FTSE 100 fell 0.35%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
<li>The Dallas Fed&#8217;s Texas manufacturing activity index rose six points to a reading of 3.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CTKB

EVTL

HSAI

TRAW

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 100 points on Monday.
The Dow traded down 0.61% to 42,725.52 while the NASDAQ fell 0.58% to 19,608.47. The S&amp;P 500 also fell, dropping, 0.59% to 5,935.35.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares fell by just 0.6% on Monday.
In trading on Monday, consumer discretionary shares dipped by 2.2%.
Top Headline
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 6% to $6.79. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 13% to $9.36. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 9% to $14.69. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) shares dropped 20% to $56.60.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 39% to $8.25. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 28% to $0.4301. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $71.32 while gold traded down 0.6% at $2,615.80.
Silver traded down 1.5% to $29.505 on Monday, while copper fell 0.7% to $4.0930.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.65%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.58%. Spain's IBEX 35 Index rose 0.01%, while London's FTSE 100 fell 0.62%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Earnings

Equities

QMCO

Crude Oil Gains 1%; Chicago PMI Falls In December

U.S. stocks were lower, with the Dow Jones index falling more than 700 points on Monday.
Shares of Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) rose sharply <a href="https://www.benzinga.com/quote/CTKB/news">during Monday's session</a>.
Cytek Biosciences announced a $50 million stock buyback program for 2025.
Cytek Biosciences shares jumped 6.1% to $6.78 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares jumped 61.5% to $1.8498.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares gained 17.7% to $20.64.</li>
<li>Mercurity Fintech Holding Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NYSE">MFH</a>) rose 16.2% to $7.88.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) gained 14% to $4.8700.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares jumped 10.8% to $9.16. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares rose 10.6% to $2.7101.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) gained 10.5% to $14.95. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) rose 7.9% to $5.04. Radiopharm reported a strategic co-development partnership with Lantheus for Australia.</li>
<li>VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) gained 5.5% to $41.11. VEON and Starlink partnered to launch direct-to-cell satellite connectivity for Kyivstar customers in Ukraine.</li>
<li>Coincheck Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNCK#NASDAQ">CNCK</a>) shares rose 5.2% to $8.94.</li>
<li>Antero Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) shares gained 4.8% to $34.91.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) rose 3.2% to $31.09.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42720292/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks With Over 4% Dividend Yields</a></li>
</ul>

Movers

CNCK

FWRD

MESO

MVST

RADX

VEON

VNET

Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. analyst Ed Arce initiated coverage on MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) with a Buy rating and announced a price target of $12. MetaVia shares closed at $1.76 on Friday. <a href="https://www.benzinga.com/quote/MTVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy rating and announced a price target of $15. Emergent BioSolutions shares closed at $8.27 on Friday. <a href="https://www.benzinga.com/quote/EBS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Swayampakula Ramakanth initiated coverage on Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) with a Buy rating and announced a price target of $110. Nuvalent shares closed at $80.30 on Friday. <a href="https://www.benzinga.com/quote/NUVL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Douglas Tsao initiated coverage on Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) with a Buy rating and announced a price target of $19. Arcutis Biotherapeutics shares closed at $14.30 on Friday. <a href="https://www.benzinga.com/quote/ARQT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Edward White initiated coverage on Artiva Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) with a Buy rating and announced a price target of $20. Artiva Biotherapeutics shares closed at $10.64 on Friday. <a href="https://www.benzinga.com/quote/ARTV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NUVL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="604" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30075444/image-232-1024x604.png" alt="" class="wp-image-711350" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30075444/image-232-1024x604.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30075444/image-232-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30075444/image-232-768x453.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30075444/image-232.png 1096w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42700627/how-to-earn-500-a-month-from-rpm-international-stock-ahead-of-q2-earnings">How To Earn $500 A Month From RPM International Stock Ahead Of Q2 Earnings</a></li>
</ul>

Initiation

Pre-Market Outlook

ARQT

ARTV

MTVA

NUVL

This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy rating and announces Price Target of $15.

HC Wainwright & Co. Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces Price Target of $15

Emergent BioSolutions Announces $50M Contract Option From BARDA To Procure Doses Of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted)

The United Nations (UN) High Commissioner for Human Rights, Volker Türk issued a call for the international community to abandon punitive drug policies, declaring that the global <a href="https://www.benzinga.com/topic/war-on-drugs">war on drugs has failed.</a>
"The evidence is clear. The so-called War on Drugs has failed, completely and utterly. And prioritizing people over punishment means more lives are saved,&#8221; said Türk while speaking at the ‘Dealing with Drugs II' <a href="https://www.amsterdam.nl/dealingwithdrugs/two/">conference </a>in Warsaw, which brought together leaders and experts from across Europe and the world last Thursday.
The UN commissioner said there is an urgent need for evidence-based, human rights-focused approaches that prioritize health and inclusion over criminalization. "These policies are simply not working—and we are failing some of the most vulnerable groups in our societies."
Read Also: <a href="https://www.benzinga.com/24/12/42349036/us-taxpayer-funds-global-drug-war-leaving-evidence-based-health-responses-behind">$13-Billion Drug War Funded By U.S. Taxpayers Fuels Violence In Developing Countries: New Report</a>
<h2 class="wp-block-heading">Radical Shift In Approach</h2>
Türk advocated for treating drug use disorders as public health issues rather than crimes.
"We need to start treating the person, not punishing the drug use disorder," he said, according to a <a href="https://news.un.org/en/story/2024/12/1157836">UN</a> press release.
"Historically, people who use drugs are marginalized, criminalized, discriminated against and left behind—very often stripped of their dignity and their rights,&#8221; he said. "We are destined to fail unless we ensure their genuine participation in formulating and implementing drug policy."
Referring to the devastating human toll of punitive drug laws, Türk called for transformative change. "The so-called war on drugs has destroyed countless lives and damaged entire communities," he said, pointing to record levels of drug-related deaths, rising drug use disorders and illegal drug production.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The ‘War on Drugs' destroyed lives and damaged communities. Criminalisation and prohibition have failed to reduce drug use and deter drug-related crimes. We need new approaches prioritising health, dignity and inclusion, guided by the Int.Guidelines onHuman Rights &amp; Drug Policy. <a href="https://t.co/WbRPaSWZGk">pic.twitter.com/WbRPaSWZGk</a>
&mdash; Volker Türk (@volker_turk) <a href="https://twitter.com/volker_turk/status/1864683554216542402?ref_src=twsrc%5Etfw">December 5, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Türk urged governments to adopt the International Guidelines on Human Rights and Drug <a href="https://www.undp.org/publications/international-guidelines-human-rights-and-drug-policy">Policy</a>. He said harm reduction measures such as decriminalization, supervised consumption sites and access to overdose reversal drugs like naloxone, which rapidly reverses the effects of an <a href="https://www.benzinga.com/topic/opioids">opioid overdose</a>.
<h2 class="wp-block-heading">US Fentanyl Problem</h2>
UN News pointed <a href="https://news.un.org/en/story/2024/12/1157836">out </a>that "North America faces an unprecedented fentanyl crisis with synthetic drugs claiming lives at an alarming rate" across the U.S. and parts of Asia and Africa.
Recent <a href="https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm#:~:text=The%20new%20data%20show%20overdose,psychostimulants%20(like%20methamphetamine)%20increased.">data</a> from the Centers for Disease Control show overdose deaths involving opioids in the U.S. (primarily <a href="https://www.benzinga.com/topic/fentanyl">fentanyl</a>) decreased from an estimated 84,181 in 2022 to&nbsp;81,083&nbsp;in 2023.&nbsp;
In March 2023, the FDA <a href="https://www.benzinga.com/general/biotech/23/03/31548384/fda-approves-first-otc-naloxone-nasal-spray-for-opioid-overdose">approved </a>Emergent BioSolutions Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) naloxone nasal spray for over-the-counter (OTC) use – the first naloxone product approved for use without a prescription. 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42146502/us-overdose-deaths-decline-as-fentanyl-potency-weakens-harm-reduction-expands">US Overdose Deaths Decline As Fentanyl Potency Weakens, Harm Reduction Expands</a></li>
</ul>
Photo: rblfmr/Shutterstock.com

Cannabis

Legal

Global

War On Drugs 'Has Failed, Completely And Utterly': UN High Commissioner Urges Evidence-Based Solutions

<ul>
<li>On June 1, 2020, Emergent announced a $628 million contract with the U.S. government to produce COVID-19 vaccines.</li>
<li>The company started producing vaccine materials for Johnson &amp; Johnson and AstraZeneca at its Baltimore facility in late 2020.&nbsp;</li>
<li>In March 2021, the facility accidentally contaminated Johnson &amp; Johnson vaccine doses with AstraZeneca ingredients.&nbsp;</li>
<li>By April 2021, the FDA halted production at the site, citing quality issues, contamination risks, and poor training.</li>
<li>Following the contamination crisis, Emergent stock price dropped by over 60% by November 2021, erasing over half the company&#8217;s market value in just months.</li>
<li>Shortly after, shareholders filed multiple lawsuits against Emergent, claiming the company misrepresented its vaccine production capabilities and hid serious quality issues.</li>
<li>Emergent BioSolutions recently agreed to pay a $40 million settlement to investors to resolve the lawsuits. Affected investors can now <a href="https://11thestate.com/cases/emergent-investor-settlement">file a claim</a> to receive the payout.</li>
</ul>
<h2 class="wp-block-heading has-medium-font-size">Overview</h2>
Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)&nbsp;secured over $1 billion in government and pharmaceutical contracts during the COVID-19 pandemic. However, in March 2021, workers at its Baltimore facility mistakenly mixed Johnson &amp; Johnson and AstraZeneca vaccine ingredients, contaminating up to 15 million J&amp;J doses and forcing AstraZeneca to discard tens of millions more. This error delayed J&amp;J's vaccine rollout and disrupted global distribution, causing Emergent stock to drop by over 50% by November 2021. Following these events, a group of shareholders sued Emergent, and recently, Emergent agreed to pay a $40 million settlement to all affected investors.
<h3 class="wp-block-heading has-medium-font-size">How It All Started: Manufacturing Failures&nbsp;</h3>
In the wake of the COVID-19 pandemic, Emergent BioSolutions <a href="https://www.globenewswire.com/news-release/2020/06/11/2046894/0/en/Emergent-BioSolutions-Signs-Agreement-to-be-U-S-Manufacturing-Partner-for-AstraZeneca-s-COVID-19-Vaccine-Candidate.html#:~:text=Development%20services%20will,public%20health%20emergencies.">positioned</a> its Bayview facility as a critical vaccine production asset. In March 2020, the company secured over $1 billion in contracts with Johnson &amp; Johnson and AstraZeneca, including a substantial government Operation Warp Speed contract.
On April 30, 2020, CEO Robert Kramer declared during an earnings call that the company had &#8220;proven manufacturing capabilities&#8221; and was prepared to scale up quickly to meet the demands of vaccine production.&nbsp;
In July 2020, following the AstraZeneca agreement, Emergent further bolstered its claims in a press release, with Kramer declaring, &#8220;Emergent is driven by our desire to advance solutions that will make an impact on this pandemic&#8220;.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="113" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/20162558/image_2024-11-20_20-25-24-1024x113.png" alt="" class="wp-image-3463" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/20162558/image_2024-11-20_20-25-24-1024x113.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/20162558/image_2024-11-20_20-25-24-300x33.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/20162558/image_2024-11-20_20-25-24-768x85.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/20162558/image_2024-11-20_20-25-24.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The company&#8217;s CDMO business unit head, Syed T. Husain, added that &#8220;Emergent stands ready alongside leading innovators to rapidly deploy our CDMO services to help meet the substantial demand for a vaccine.&#8220;
By early 2021, Emergent shares were trading above $90, fueled by high expectations for the company's role in vaccine production.&nbsp;
However, despite positive public messaging, internal audits and inspections in the summer of 2020 uncovered serious issues at Emergent BioSolutions' manufacturing facilities.&nbsp;
Reports highlighted poor staff training, equipment failures, and inadequate quality control measures, revealing long-standing problems within the company&#8217;s operations. One audit found that &#8220;the flow of workers and materials through the plant was not adequately controlled to prevent mix-ups or contamination.&#8221; Another audit discovered that a manager had &#8220;knowingly deviated&#8221; from standard procedures.
After that, in November 2020, AstraZeneca representatives visiting Emergent&#8217;s Bayview facility raised concerns about poor oversight and GMP compliance.&nbsp;
Emergent&#8217;s VP of Manufacturing acknowledged these issues, mentioning trash buildup in hallways and lapses in GMP standards. An external consultant also warned that the facility was &#8220;NON-CGMP compliant&#8221; and at regulatory risk, but production still continued.
<h3 class="wp-block-heading has-medium-font-size">Contamination Crisis at Emergent's Facility</h3>
In March 2021, a major contamination incident at Emergent's Baltimore facility revealed significant oversight failures. Millions of Johnson &amp; Johnson vaccine doses were mixed with AstraZeneca ingredients, an issue initially detected by Johnson &amp; Johnson's lab in the Netherlands, not Emergent. 
The contamination forced the disposal of tens of millions of AstraZeneca doses and delayed the delivery of approximately 100 million Johnson &amp; Johnson doses during a critical phase of the pandemic.&nbsp;
Following this disclosure, Emergent issued a press release, stating that their &#8220;quality control systems worked as designed&#8221; and that discarding a batch of bulk drug substance &#8220;occasionally happens during vaccine manufacturing.&#8221;&nbsp;
However, that same day the Associated Press released FDA documents obtained through FOIA requests, revealing a history of quality control issues at Emergent&#8217;s facilities dating back to 2017.
FDA leaders reported that the company &#8220;hired a lot of individuals not as familiar with vaccine manufacturing that did not have adequate training.&#8221;&nbsp;
Inspectors found several issues at Emergent's facility, including mismanaged waste, peeling paint, and cluttered equipment. They also discovered that some quality checks were removed from vaccines before an FDA visit in February 2021.&nbsp;
Later, it came to light that Emergent had been forced to destroy vaccine materials equivalent to nearly 400 million doses — much more than the previously reported 85 million.
The situation worsened on November 4, 2021, when Emergent announced that the Department of Health and Human Services had cancelled its $628 million contract, requiring the company to reverse $86 million in Q3 2021 revenue and reduce its contract backlog by $180 million.
The impact on investors was clear as Emergent's stock price dropped by over 60%, from more than $120 in early 2021 to below $45 by November 2021.
<figure class="wp-block-image is-resized"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXeIIZlLXwwooy_Zuo42Ez05mIVStfl0HOwUqkb9SlYYDcrmYOLAsAZF0seiSDHOA3ONme9YjpCgNgGOq0vGoQc-apf2vdPLSufxtKjA92BHR-VPz2Bk12OYqeUoyRBv-UZ97kKnZU0RrwHGwCBSKGT8671r?key=KYxIxnLygQzR6Mc3yd4O5SaK" alt="" style="width:624px" /></figure>
These disclosures and the sharp drop in stock price led shareholders to file multiple lawsuits against Emergent, accusing the company of misrepresenting its vaccine production capabilities and concealing serious quality issues.
<h3 class="wp-block-heading has-medium-font-size">Resolving The Case</h3>
After three years of legal proceedings, in September 2024, Emergent agreed to pay $40 million to settle the lawsuit from shareholders. If you invested in Emergent, you may be eligible to <a href="https://11thestate.com/cases/emergent-investor-settlement">file for a portion</a> of the settlement to recover your losses.
As of now, Emergent BioSolutions has made significant progress in its recovery, securing a $50 million settlement with Johnson &amp; Johnson and driving a broader transformation under CEO Joe Papa. In Q3 2024, the company saw a 9% revenue increase to $293.8 million and secured vital government contracts, including a $250 million order to produce vaccines for anthrax, botulism, and smallpox. It also sold its Camden facility for $30 million to streamline operations. However, its stock remains far below previous highs, trading at $8 in November 2024 — a 93.6% decline from its $125 peak in 2021, showing that there is still a long road ahead for a recovery.

Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement

<a href="https://worldhealthorg.shinyapps.io/mpx_global/" title="https://worldhealthorg.shinyapps.io/mpx_global/">https://worldhealthorg.shinyapps.io/mpx_global/</a>

World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern

<h3 class="wp-block-heading">Trump Will Fix It&nbsp;</h3>
In my previous post (<a href="https://www.zerohedge.com/news/2024-11-06/post-trump-victory-trade">The Post-Trump Victory Trade</a>), I highlighted a half dozen stocks in which my subscribers and I had positions that had double digit gains the day after Trump&#8217;s election victory. In response, a commenter wrote, &#8220;Well, I didn&#8217;t like any of those trades, so I will stick to my Gold and Silver.&#8221;.&nbsp;
As it happened, the day after Trump&#8217;s victory, was also the day of the &#8220;<a href="https://www.zerohedge.com/the-market-ear/great-gold-puke">Great Gold Puke</a>&#8220;, as The Market Ear put it:&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><h3 class="wp-block-heading">All good things&#8230;</h3>
&#8230;.must come to an end. Gold is puking, putting in the biggest down candle in forever as it breaks below the short term trend channel. The 50 day comes in around $2635, and the bigger trend line around $2600.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="532" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-1024x532.png" alt="" class="wp-image-3141" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-1024x532.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-300x156.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold-768x399.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08195017/Gold.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> 
<cite>Refinitiv</cite></blockquote>
Why would gold tumble after Trump&#8217;s victory? Perhaps there&#8217;s a clue in the Trump campaign&#8217;s slogan, &#8220;Trump will fix it&#8221;. One of the things Trump will fix is the elevated geopolitical risk the world has seen over the last few years, starting with the Russia-Ukraine War, and extending to the wars in the Mideast between Israel and Hamas, and Israel and Iran, and tensions between China and Taiwan.&nbsp;
<h3 class="wp-block-heading">Geopolitical Risk Is Already Starting To Ebb</h3>
The geopolitical risk premium is a key factor influencing the price of precious metals like gold and silver, as they are traditionally seen as a haven during times of instability and war. Given that, note what has happened since Trump&#8217;s victory:&nbsp;
<ul>
<li>Hamas <a href="https://x.com/DonaldJTrumpJr/status/1854516506169585796">has called for</a> an end to its war with Israel. </li>
<li>Russian President Vladimir Putin&nbsp;<a href="https://www.zerohedge.com/geopolitical/putin-praises-courageous-trump-hints-ukraine-talks-phone-call-likely">has congratulated Trump</a>&nbsp;on his victory, praised Trump&#8217;s bravery during the first assassination attempt on him, and expressed an openness toward talks aimed at ending the Ukraine war. Peace between the U.S. and Russia would facilitate peace in the Mideast and elsewhere, given Russia&#8217;s ties to Iran, China, and other key countries.&nbsp;</li>
<li>China&#8217;s President Xi <a href="https://x.com/XHNews/status/1854396381982830623">also extended congratulations</a> and an olive branch to Trump.</li>
</ul>
If Trump succeeds in ending the wars in Eastern Europe and the Mideast, and calming tensions across the Taiwan Strait, that would further reduce gold&#8217;s geopolitical risk premium.&nbsp;
<h3 class="wp-block-heading">The Deflationary Potential Of Trump&#8217;s Domestic Policies </h3>
You&#8217;re probably thinking now that even if peace starts to break out, high inflation is baked into the cake because of government spending, and that should boost the price of gold. Consider, though, the deflationary potential of Trump&#8217;s proposed policies, and those of his close allies.&nbsp;&nbsp;
<ul>
<li>Trump&#8217;s tariffs. Critics of tariffs often point out that they are, effectively, a regressive tax on domestic consumers. This is actually true, and like all regressive taxes, they are deflationary. Just as throwing money and low income Americans boosted inflation during COVID, an effective regressive tax on them would cool inflation.&nbsp;</li>
<li>Trump&#8217;s deportations.&nbsp;Deporting millions of illegal aliens&#8211;or deporting a smaller number and prompting millions more to self-deport&#8211;will have a deflationary effect on sectors such as housing, as there will be fewer consumers competing for the same number of homes.&nbsp;</li>
<li>RFK, Jr.&#8217;s campaign against chronic disease. Every case of diabetes and other chronic diseases RFK, Jr. can prevent with changes to American food policy means a reduction of tens of thousands, if not hundreds of thousands of dollars in health care spending. That would cool healthcare inflation.&nbsp;</li>
<li>Elon Musk&#8217;s Department Of Government Efficiency. Elon Musk has spoken about slashing the number of federal employees (something Vivek Ramaswamy pointed out could be done while avoiding Civil Service regulations) and cutting government waste. That would be deflationary too.&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Much Of This Is Likely To Happen&nbsp;</h3>
We all remember how Trump was stymied in his first term, but he is in a much stronger position now. He won a landslide victory, and is now the undisputed leader of the Republican Party. Plus, he has much smarter, and more competent people on his side now, such as Elon Musk. None of this is particularly good for gold and silver prices.&nbsp;
<h3 class="wp-block-heading">Taking My Own Counsel&nbsp;</h3>
On Thursday, I exited the two gold positions I had, in&nbsp;Olra Mining&nbsp;(ORLA) and IAMGOLD&nbsp;(IAG), as you can see below, in my list of trade exits for this week.&nbsp;
Stocks or Exchange Traded Products
<ol>
<li>Lantheus Holdings&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>). Bought at $94.84 on&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-8152024/comment/65674302" target="_blank" rel="noreferrer noopener">8/16/2024</a>; stopped out at $96.99 on&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-8152024/comment/75900731" target="_blank" rel="noreferrer noopener">11/6/2024</a>.&nbsp;Profit: 2.3%.</li>
<li>Orla Mining&nbsp;(<a href="https://substack.com/discover/stocks/ORLA" target="_blank" rel="noreferrer noopener">ORLA 4.11%↑</a>). Bought for an effective price of $2.90 on&nbsp;<a href="https://portfolioarmor.substack.com/p/an-oversold-gold-miner" target="_blank" rel="noreferrer noopener">11/17/2023</a>&nbsp;(I sold $5 strike puts on it for $2.10, and those puts exercised on 11/17/2023); sold for $4.60 on&nbsp;<a href="https://portfolioarmor.substack.com/p/an-oversold-gold-miner/comment/76086457" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 59%.</li>
</ol>
Options
<ol>
<li>Call spread on&nbsp;Super Micro Computer&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>). Entered at a net debit of $0.33 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-ai-da2" target="_blank" rel="noreferrer noopener">11/4/2024</a>; will expire worthless on 11/8/2024.&nbsp;Loss: 100%.</li>
<li>Calls on&nbsp;IAMGOLD&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>). Bought for $0.75 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-gold" target="_blank" rel="noreferrer noopener">10/8/2024</a>; sold (second half) for $1.15 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-gold/comment/76091886" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 53%.</li>
<li>Calls on&nbsp;Emergent BioSolutions&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>). Bought for $2.05 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-biotech" target="_blank" rel="noreferrer noopener">8/30/2024</a>; sold for $4.10 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-biotech/comment/76086955" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 100%.</li>
<li>Call spread on TG Therapeutics (<a href="https://substack.com/discover/stocks/TGTX" target="_blank" rel="noreferrer noopener">TGTX 2.33%↑</a>). Entered at net debit of $0.33 on <a href="https://portfolioarmor.substack.com/p/trade-alert-biotech" target="_blank" rel="noreferrer noopener">8/30/2024</a>; exited at a net credit of $0.94 on <a href="https://portfolioarmor.substack.com/p/trade-alert-biotech/comment/76253379" target="_blank" rel="noreferrer noopener">11/8/2024</a>. Profit: 184%.</li>
<li>Call spread on&nbsp;Tesla&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). Entered at a net debit of $1.63 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-evs/comment/76235063" target="_blank" rel="noreferrer noopener">4/8/2024</a>; exited at net credit of $4.74 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-evs/comment/76235063" target="_blank" rel="noreferrer noopener">11/8/2024</a>.&nbsp;Profit: 191%.</li>
<li>Call spread on&nbsp;Innodata&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>). Entered at $0.33 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-24f" target="_blank" rel="noreferrer noopener">8/13/2024</a>; exited at $0.97 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-24f/comment/76235562" target="_blank" rel="noreferrer noopener">11/8/2024</a>.&nbsp;Profit: 194%.</li>
<li>Call spread on&nbsp;Powell Industries&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>). Entered at a net debit of $1.60 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-industrial" target="_blank" rel="noreferrer noopener">8/13/2024</a>; exited at a net credit of $4.75 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-industrial/comment/76088210" target="_blank" rel="noreferrer noopener">11/7/2024</a>.&nbsp;Profit: 197%.</li>
<li>Calls on&nbsp;Travelzoo&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>). Bought at $1 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-crypto" target="_blank" rel="noreferrer noopener">7/23/2024</a>; sold (half) at $8.30 on&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-small-cap-crypto/comment/75897738" target="_blank" rel="noreferrer noopener">11/6/2024</a>.&nbsp;Profit: 730%.</li>
</ol>
<h2 class="wp-block-heading">The Post-Trump Victory Trade We&#8217;re Buying Now</h2>
Trump&#8217;s victory means China is going to have to stimulate its economy more aggressively (because it won&#8217;t be able to export as much to the U.S. with Trump&#8217;s tariff).&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;Donald Trump's second US presidency is likely to prompt aggressive China stimulus&quot; &#8211; Devan Kaloo, global head of equities at abrdn <a href="https://t.co/hVPBus1Bde">https://t.co/hVPBus1Bde</a>
&mdash; zerohedge (@zerohedge) <a href="https://twitter.com/zerohedge/status/1854379142952726692?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
That stimulus will boost companies doing business in China&#8217;s domestic market. One of those companies hit our&nbsp;<a href="https://portfolioarmor.substack.com/p/top-names-1172024">top ten names</a>&nbsp;last night, and my subscribers and I placed a trade on it today.&nbsp;
<figure class="wp-block-image size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-trump-china"><img loading="lazy" decoding="async" width="922" height="816" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade.jpg" alt="" class="wp-image-3142" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade.jpg 922w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade-300x266.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08200010/Trump-China-Trade-768x680.jpg 768w" sizes="(max-width: 922px) 100vw, 922px" /></a><figcaption class="wp-element-caption">Click on the image to go to the post. </figcaption></figure>
If you&#8217;d like a heads up when we place our next trade, feel free to subscribe to our trading Substack/occasional email list below.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1.jpg" alt="" class="wp-image-3152" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204717/Widget-1-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>
And if you are concerned about market risk, you can download our optimal hedging app by pointing your iPhone camera at the QR code below, or by clicking on it. 
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/08204833/QR-Code-2.jpg" alt="" class="wp-image-3155" /></a></figure>

Economics

INOD

LNTH

POWL

SMCI

TSLA

TZOO

After Trump's Win, It's Time To Take Profits On Gold

<a href="https://www.business-standard.com/health/new-study-claims-mpox-clade-la-has-evolved-to-spread-from-human-to-human-nc-124111100528_1.html" title="https://www.business-standard.com/health/new-study-claims-mpox-clade-la-has-evolved-to-spread-from-human-to-human-nc-124111100528_1.html">https://www.business-standard.com/health/new-study-claims-mpox-clade-la-has-evolved-to-spread-from-human-to-human-nc-124111100528_1.html</a>

India's Business Standard Reported New Study Claims Mpox Clade la Has Evolved To Spread From Human To Human, Citing October 24 Uploaded Paper On Virologica

Despite claiming over 100,000 lives annually, the U.S. overdose crisis received minimal attention during the recent presidential campaign, which concluded with Donald Trump&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/11/41776510/cannabis-industry-leaders-react-to-trump-victory-expect-changes">victory</a>. This oversight comes as overdose deaths continue to rise among Black and Indigenous Americans, revealing a growing racial disparity in the epidemic.
<h3 class="wp-block-heading">Rising Racial Disparities In Overdose Deaths</h3>
According to a Stateline analysis of federal data <a href="https://kentuckylantern.com/2024/11/04/overdose-deaths-are-rising-among-black-and-indigenous-americans/">covered</a> by Tim Henderson, overdose deaths among white Americans have declined, but deaths among people of color have increased. In 2023, Black and Native Americans experienced overdose death rates of 49.5 and 39.8 per 100,000 people, respectively, surpassing white rates. Health experts attribute this to a lack of targeted resources and funding in nonwhite communities.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
&#8220;It is our contention that Black harm reduction isn't about drug use, it's about the harms of not being a white person in this country,&#8221; said Tracie Gardner, co-director of the National Black Harm Reduction Network. Communities of color often struggle to access harm reduction services, which are predominantly designed and led by white institutions.
<h3 class="wp-block-heading">Minimal Campaign Attention</h3>
Throughout the campaign, Trump and his opponent, Vice President Kamala Harris, <a href="https://www.benzinga.com/markets/cannabis/24/10/41299527/kamala-harris-defends-immigration-policy-at-latino-town-hall-criticizes-trumps-border-stance">focused largely on border security and drug enforcement</a> rather than harm reduction strategies.&nbsp;
As a recent Fitler Mag <a href="https://filtermag.org/overdose-presidential-election/">article</a> notes, Trump&#8217;s official platform emphasized escalating the drug war, proposing measures like deploying the U.S. Navy to impose a &#8220;full Fentanyl Blockade&#8221; and cracking down on cartels. Harris, while mentioning a commitment to ending the opioid epidemic, highlighted her background in prosecutions and supported increased border security measures.
Public health experts criticize this approach for failing to address the root causes of the crisis. Kassandra Frederique, executive director of the Drug Policy Alliance, noted that efforts have &#8220;ultimately fallen short of the scale and magnitude this crisis demands.&#8221;
<h3 class="wp-block-heading">Rising Demand For Narcan</h3>
Amid this policy void, demand for naloxone—commonly known by the brand name Narcan—is increasing sharply. Over 250 companies, universities and organizations have pledged to provide free doses of the overdose-reversing medication, <a href="https://www.npr.org/sections/shots-health-news/2024/10/08/nx-s1-5145832/250-companies-schools-and-organizations-pledge-to-provide-overdose-antidote-naloxone">according</a> to NPR. Major corporations like Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), United Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and the National Hockey League are participating in this national effort to curb fatalities.
White House officials noted that the wider availability of naloxone has contributed to a recent 10% decline in overall overdose deaths. &#8220;From airlines to classrooms, from offices to sports arenas, we are grateful to have hundreds of voluntary commitments from organizations and businesses across the country,&#8221; stated Dr. Rahul Gupta, the Biden administration&#8217;s drug czar, prior to the election.
However, experts caution that fatalities remain high, especially among marginalized communities.
<h3 class="wp-block-heading">Emergent BioSolutions Sees Stock Surge</h3>
Meanwhile, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), the manufacturer of Narcan, has seen its stock perform strongly in 2024. With a diverse portfolio addressing public health threats, the company&#8217;s financial recovery and strategic government contracts position it favorably in the market, <a href="https://www.insidermonkey.com/blog/emergent-biosolutions-inc-ebs-a-standout-among-best-performing-cheap-stocks-in-2024-1371074/">noted</a> Insider Monkey. EBS reported significant revenue growth and reduced debt, contributing to a year-to-date share price gain of over 280%.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/03/31549189/fda-approves-over-the-counter-sale-of-opioid-reversal-drug-narcan">FDA Approves Over The Counter Sale Of Opioid Reversal Drug Narcan</a>
Analysts attribute part of Emergent&#8217;s success to the increasing recognition of naloxone&#8217;s importance in combating the overdose crisis. As more organizations stock Narcan, the company&#8217;s role becomes ever more critical.
<h3 class="wp-block-heading">Barriers To Harm Reduction Access Persist</h3>
As the new administration takes office, the neglect of the overdose crisis in election debates raises questions about the future of <a href="http://benzinga.com/topic/harm-reduction">harm reduction</a> policies under the new administration. Advocates urge the government to prioritize effective strategies over punitive measures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41780260/canopy-growth-and-other-top-cannabis-companies-to-report-earnings-will-results-get-pot-stocks-on">Canopy Growth And Other Top Cannabis Companies To Report Earnings: Will Results Get Pot Stocks On Track Following Post-Election Dip?</a></li>
</ul>

Government

Health Care

Politics

AMZN

Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise

On Thursday, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.
The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265&nbsp;million–$315 million, and missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $297.5 million</a>.
The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago,&nbsp;beating <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41786475/emergent-biosolutions-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">the consensus of $0.14</a>.
Revenues from Narcan&nbsp;(naloxone HCl) Nasal Spray decreased 33% to $95.3 million, primarily driven by the discontinuation of prescription Narcan&nbsp;due to the launch of over-the-counter Narcan&nbsp;in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC Narcan.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41026819/emergent-biosolutions-confirms-orders-worth-400m-related-to-smallpox-mpox-vaccines" rel="noreferrer noopener">Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines</a>
Revenues from Anthrax MCM fell 65% to $11.4 million, and Smallpox MCM sales jumped more than fivefold to $132.7 million.
Guidance: Emergent BioSolutions updated its 2024 revenue guidance from $1.05 billion &#8211; $1.125 billion to $1.065 billion &#8211; $1.125 billion, compared to the consensus of $1.123 billion.
The updated guidance includes commercial product sales of $420&nbsp;million &#8211;&nbsp;$430 million compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40226161/vaccine-maker-emergent-biosolutions-expects-deeper-losses-in-2024-stock-sinks" rel="noreferrer noopener">prior guidance of </a>$450 million – $480 million.
MCM Product sales outlook of $510&nbsp;million &#8211; $550 million, compared to $455&nbsp;million – $490 million expected earlier.
Services segment sales are expected to be $105&nbsp;million &#8211; $110 million, lower than the prior range of $120&nbsp;million – $130 million.
The company expects a 2024 net loss of $203 million &#8211; $183 million, compared to the previous loss range of $314 million – $274 million, and an adjusted EBITDA of $180 million &#8211; $200 million compared to previous forecast of $140 million &#8211; $180 million.
Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included in a trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41789320/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-of-brincidofo" rel="noreferrer noopener">Disease Control and Prevention</a>.
The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus. The trial is scheduled to begin in the coming weeks in the Democratic Republic of Congo and neighboring countries.
Price Action: EBS stock is up 28.3% at $11.80 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41816035/ralph-lauren-soars-as-q2-results-outpace-expectations-ceo-eyes-holiday-season-with-raised-revenue-g" target="_blank" rel="noreferrer noopener">Ralph Lauren Soars As Q2 Results Outpace Expectations—CEO Eyes Holiday Season With Raised Revenue Goals</a></li>
</ul>

Guidance

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

Emergent BioSolutions up 10% on HC Wainwright buy initiation

Emergent BioSolutions (EBS) is up 5.3%, or 49c to $9.74. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Emergent BioSolutions rises 5.3%

Vaccine stocks gain amid uptick in flu, COVID-19, RSV

Emergent BioSolutions (EBS) announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax to th...

Emergent BioSolutions exercises $20M option to supply DoD with BioThrax

Emergent BioSolutions: Stock Is A Likely Winner In 2025

Hikma Pharmaceuticals (HKMPF) announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (EBS) for the sale of Kl...

Emergent BioSolutions, Hikma enter partnership for sale of Kloxxado nasal spray

Emergent BioSolutions (EBS) announces that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma P...

Emergent BioSolutions gains exclusive commercial rights to KLOXXADO

EBS obtains rights to Hikma's Kloxxado naloxone spray

Emergent Biosolutions ( ($EBS) ) has shared an announcement. On January 15, 2025, Joe C. Papa, the CEO of Emergent BioSolutions, presented at the 4...

Emergent BioSolutions Outlines Growth at J.P. Morgan Conference

Africa CDC's support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabl...

Emergent BioSolutions starts enrollment in Africa or cDC-led MPox study

BNTX

CVAC

NVAX

Screenshot 2024-09-18 at 12.30.33 AM

BVNKF

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Press Releases

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS

Management

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

Comments

Emergent BioSolutions

空売り

Emergent BioSolutions (NYSE:EBS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル